<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161015</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-0110</org_study_id>
    <nct_id>NCT03161015</nct_id>
  </id_info>
  <brief_title>Single-Dose PK Study of GBT440 in Subjects With Renal Impairment</brief_title>
  <official_title>A Non-Randomized, Open-Label, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics of GBT440 in Subjects With Renal Impaired Function to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral
      dose of GBT440 administered in subjects with mild, moderate, or severe renal impairment
      disease and healthy subjects with normal renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 40 adult subjects will be enrolled. Safety and PK assessments will be performed at
      selected time points throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">May 25, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple-center, nonrandomized, open-label, parallel group study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of GBT440 in subjects with severe, moderate, or mild renal impairment versus subjects with normal renal function</measure>
    <time_frame>28 days max</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of GBT440 in subjects with severe, moderate, or mild renal impairment versus subjects with normal renal function</measure>
    <time_frame>28 days max</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of GBT440 in subjects with severe, moderate, or mild renal impairment versus subjects with normal renal function</measure>
    <time_frame>28 days max</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of GBT440 in subjects with severe, moderate, or mild renal impairment versus subjects with normal renal function</measure>
    <time_frame>28 days max</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-related Adverse events</measure>
    <time_frame>28 days max</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>GBT440 Dose 1: Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR &lt; 30 mL/min/1.73m2, not on dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 1: Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mL/min/1.73m2 = or &lt; eGFR &lt; 60 mL/min/1.73m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 1: Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mL/min/1.73m2 = or &lt; eGFR &lt; 90 mL/min/1.73m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 1: Normal Renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR &gt; or = 90 mL/min/1.73m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <description>Oral</description>
    <arm_group_label>GBT440 Dose 1: Severe Renal Impairment</arm_group_label>
    <arm_group_label>GBT440 Dose 1: Moderate Renal Impairment</arm_group_label>
    <arm_group_label>GBT440 Dose 1: Mild Renal Impairment</arm_group_label>
    <arm_group_label>GBT440 Dose 1: Normal Renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  Males or females, 18 to 80 years old

          -  Willing and able to give written informed consent

        Subjects with renal impairment:

          -  Severe renal impairment (eGFR &lt; 30 mL/min/1.73m2, not on dialysis)

          -  Moderate renal impairment (30 mL/min/1.73m2 = or &lt; eGFR &lt; 60 mL/min/1.73m2)

          -  Mild renal impairment (60 mL/min/1.73m2 = or &lt; eGFR &lt; 90 mL/min/1.73m2)

        Healthy subjects:

          -  Match in age, gender and body mass index with renal impaired subjects

          -  Healthy and without clinically significant abnormalities in vital signs, ECGs,
             physical exam, clinical laboratory evaluations, medical and surgical history

        Exclusion Criteria:

        All subjects:

          -  Participation in another clinical trial of an investigational drug (or medical device)
             within 30 days of the last dose of investigational drug or 5 half lives whichever is
             longer, prior to screening, or is currently participating in another trial of an
             investigational drug (or medical device)

          -  Any signs or symptoms of acute illness at screening or Day -1

          -  History or presence of clinically significant allergic, hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological
             disease

        Subjects with renal impairment:

        - History of clinically significant hepatic disease e.g. hepatitis, cirrhosis and or liver
        enzymes (ALT, AST, GGT and total bilirubin) &gt; 5 times the upper limit of normal within the
        past year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Washington</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OCRC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

